BRISTOL-MYERS SQUIBB CO (BMY) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:BMY - US1101221083 - Common Stock
54.2599 USD
-1 (-1.81%)
We assign a fundamental rating of 6 out of 10 to BMY. BMY was compared to 191 industry peers in the Pharmaceuticals industry. While BMY has a great profitability rating, there are some minor concerns on its financial health. BMY may be a bit undervalued, certainly considering the very reasonable score on growth BMY also has an excellent dividend rating. With these ratings, BMY could be worth investigating further for value and dividend investing!.
1. Profitability
1.1 Basic Checks
- In the past year BMY was profitable.
- BMY had a positive operating cash flow in the past year.
- In multiple years BMY reported negative net income over the last 5 years.
- BMY had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- BMY has a Return On Assets of 6.23%. This is amongst the best in the industry. BMY outperforms 87.43% of its industry peers.
- BMY has a Return On Equity of 32.55%. This is amongst the best in the industry. BMY outperforms 94.76% of its industry peers.
- With an excellent Return On Invested Capital value of 18.43%, BMY belongs to the best of the industry, outperforming 95.81% of the companies in the same industry.
- BMY had an Average Return On Invested Capital over the past 3 years of 12.30%. This is in line with the industry average of 12.84%.
- The 3 year average ROIC (12.30%) for BMY is below the current ROIC(18.43%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROIC | 18.43% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)12.3%
ROIC(5y)10.36%
1.3 Margins
- With an excellent Profit Margin value of 12.57%, BMY belongs to the best of the industry, outperforming 84.82% of the companies in the same industry.
- With an excellent Operating Margin value of 33.51%, BMY belongs to the best of the industry, outperforming 95.29% of the companies in the same industry.
- In the last couple of years the Operating Margin of BMY has declined.
- BMY has a Gross Margin of 73.15%. This is amongst the best in the industry. BMY outperforms 80.63% of its industry peers.
- BMY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% |
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so BMY is creating value.
- BMY has less shares outstanding than it did 1 year ago.
- The number of shares outstanding for BMY has been reduced compared to 5 years ago.
- The debt/assets ratio for BMY is higher compared to a year ago.
2.2 Solvency
- An Altman-Z score of 2.25 indicates that BMY is not a great score, but indicates only limited risk for bankruptcy at the moment.
- With a Altman-Z score value of 2.25, BMY perfoms like the industry average, outperforming 59.69% of the companies in the same industry.
- The Debt to FCF ratio of BMY is 3.20, which is a good value as it means it would take BMY, 3.20 years of fcf income to pay off all of its debts.
- BMY has a Debt to FCF ratio of 3.20. This is amongst the best in the industry. BMY outperforms 87.96% of its industry peers.
- BMY has a Debt/Equity ratio of 2.41. This is a high value indicating a heavy dependency on external financing.
- Looking at the Debt to Equity ratio, with a value of 2.41, BMY is doing worse than 79.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Altman-Z | 2.25 |
ROIC/WACC2.1
WACC8.77%
2.3 Liquidity
- A Current Ratio of 1.27 indicates that BMY should not have too much problems paying its short term obligations.
- The Current ratio of BMY (1.27) is worse than 78.01% of its industry peers.
- BMY has a Quick Ratio of 1.17. This is a normal value and indicates that BMY is financially healthy and should not expect problems in meeting its short term obligations.
- BMY has a worse Quick ratio (1.17) than 75.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 460.68% over the past year.
- The earnings per share for BMY have been decreasing by -24.57% on average. This is quite bad
- The Revenue has been growing slightly by 1.26% in the past year.
- The Revenue has been growing by 13.06% on average over the past years. This is quite good.
EPS 1Y (TTM)460.68%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-9.44%
Revenue 1Y (TTM)1.26%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%2.77%
3.2 Future
- The Earnings Per Share is expected to grow by 35.29% on average over the next years. This is a very strong growth
- Based on estimates for the next years, BMY will show a decrease in Revenue. The Revenue will decrease by -5.06% on average per year.
EPS Next Y478.44%
EPS Next 2Y130.59%
EPS Next 3Y73.3%
EPS Next 5Y35.29%
Revenue Next Year0.23%
Revenue Next 2Y-3.95%
Revenue Next 3Y-3.2%
Revenue Next 5Y-5.06%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 8.27, which indicates a very decent valuation of BMY.
- BMY's Price/Earnings ratio is rather cheap when compared to the industry. BMY is cheaper than 92.15% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.38, BMY is valued rather cheaply.
- BMY is valuated reasonably with a Price/Forward Earnings ratio of 8.95.
- Based on the Price/Forward Earnings ratio, BMY is valued cheaply inside the industry as 89.01% of the companies are valued more expensively.
- The average S&P500 Price/Forward Earnings ratio is at 24.29. BMY is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.27 | ||
| Fwd PE | 8.95 |
4.2 Price Multiples
- 92.67% of the companies in the same industry are more expensive than BMY, based on the Enterprise Value to EBITDA ratio.
- Based on the Price/Free Cash Flow ratio, BMY is valued cheaply inside the industry as 94.76% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.22 | ||
| EV/EBITDA | 6.85 |
4.3 Compensation for Growth
- BMY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of BMY may justify a higher PE ratio.
- A more expensive valuation may be justified as BMY's earnings are expected to grow with 73.30% in the coming years.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y130.59%
EPS Next 3Y73.3%
5. Dividend
5.1 Amount
- BMY has a Yearly Dividend Yield of 4.45%, which is a nice return.
- Compared to an average industry Dividend Yield of 0.40, BMY pays a better dividend. On top of this BMY pays more dividend than 97.38% of the companies listed in the same industry.
- BMY's Dividend Yield is rather good when compared to the S&P500 average which is at 1.84.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.45% |
5.2 History
- The dividend of BMY is nicely growing with an annual growth rate of 11.67%!
- BMY has been paying a dividend for at least 10 years, so it has a reliable track record.
- BMY has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)11.67%
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
- 82.81% of the earnings are spent on dividend by BMY. This is not a sustainable payout ratio.
- The dividend of BMY is growing, but earnings are growing more, so the dividend growth is sustainable.
DP82.81%
EPS Next 2Y130.59%
EPS Next 3Y73.3%
NYSE:BMY (1/20/2026, 3:36:09 PM)
54.2599
-1 (-1.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-30 2025-10-30/bmo
Earnings (Next)02-05 2026-02-05/amc
Inst Owners81.87%
Inst Owner Change0.12%
Ins Owners0.02%
Ins Owner Change-1.33%
Market Cap110.46B
Revenue(TTM)48.03B
Net Income(TTM)6.04B
Analysts70
Price Target56.91 (4.88%)
Short Float %1.8%
Short Ratio2.5
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.45% |
Yearly Dividend2.42
Dividend Growth(5Y)11.67%
DP82.81%
Div Incr Years3
Div Non Decr Years3
Ex-Date01-02 2026-01-02 (0.63)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.98%
Min EPS beat(2)6.92%
Max EPS beat(2)35.04%
EPS beat(4)4
Avg EPS beat(4)18.72%
Min EPS beat(4)6.92%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)16.52%
EPS beat(12)11
Avg EPS beat(12)11.66%
EPS beat(16)15
Avg EPS beat(16)10.13%
Revenue beat(2)2
Avg Revenue beat(2)4.61%
Min Revenue beat(2)2.43%
Max Revenue beat(2)6.79%
Revenue beat(4)4
Avg Revenue beat(4)4.63%
Min Revenue beat(4)2.43%
Max Revenue beat(4)6.79%
Revenue beat(8)8
Avg Revenue beat(8)3.95%
Revenue beat(12)9
Avg Revenue beat(12)1.94%
Revenue beat(16)11
Avg Revenue beat(16)1.64%
PT rev (1m)6.03%
PT rev (3m)8.15%
EPS NQ rev (1m)-2.77%
EPS NQ rev (3m)1.7%
EPS NY rev (1m)-0.19%
EPS NY rev (3m)0.14%
Revenue NQ rev (1m)0.05%
Revenue NQ rev (3m)1.81%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)1.36%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.27 | ||
| Fwd PE | 8.95 | ||
| P/S | 2.3 | ||
| P/FCF | 7.22 | ||
| P/OCF | 6.65 | ||
| P/B | 5.95 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.85 |
EPS(TTM)6.56
EY12.09%
EPS(NY)6.06
Fwd EY11.17%
FCF(TTM)7.52
FCFY13.85%
OCF(TTM)8.16
OCFY15.05%
SpS23.6
BVpS9.11
TBVpS-11.62
PEG (NY)0.02
PEG (5Y)N/A
Graham Number36.68
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROCE | 23.41% | ||
| ROIC | 18.43% | ||
| ROICexc | 24.22% | ||
| ROICexgc | 123.43% | ||
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% | ||
| FCFM | 31.86% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)12.3%
ROIC(5y)10.36%
ROICexc(3y)14.46%
ROICexc(5y)12.33%
ROICexgc(3y)78.95%
ROICexgc(5y)80.83%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexgc growth 3Y-16.88%
ROICexgc growth 5Y3.18%
ROICexc growth 3Y7.41%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score6
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Debt/EBITDA | 2.13 | ||
| Cap/Depr | 26.84% | ||
| Cap/Sales | 2.75% | ||
| Interest Coverage | 7.66 | ||
| Cash Conversion | 79.11% | ||
| Profit Quality | 253.39% | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | 2.25 |
F-Score6
WACC8.77%
ROIC/WACC2.1
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)460.68%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-9.44%
EPS Next Y478.44%
EPS Next 2Y130.59%
EPS Next 3Y73.3%
EPS Next 5Y35.29%
Revenue 1Y (TTM)1.26%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%2.77%
Revenue Next Year0.23%
Revenue Next 2Y-3.95%
Revenue Next 3Y-3.2%
Revenue Next 5Y-5.06%
EBIT growth 1Y44.7%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year263.97%
EBIT Next 3Y49.92%
EBIT Next 5Y23.19%
FCF growth 1Y30.91%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y28.71%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%
BRISTOL-MYERS SQUIBB CO / BMY FAQ
What is the ChartMill fundamental rating of BRISTOL-MYERS SQUIBB CO (BMY) stock?
ChartMill assigns a fundamental rating of 6 / 10 to BMY.
What is the valuation status for BMY stock?
ChartMill assigns a valuation rating of 9 / 10 to BRISTOL-MYERS SQUIBB CO (BMY). This can be considered as Undervalued.
What is the profitability of BMY stock?
BRISTOL-MYERS SQUIBB CO (BMY) has a profitability rating of 7 / 10.
Can you provide the financial health for BMY stock?
The financial health rating of BRISTOL-MYERS SQUIBB CO (BMY) is 5 / 10.
What is the expected EPS growth for BRISTOL-MYERS SQUIBB CO (BMY) stock?
The Earnings per Share (EPS) of BRISTOL-MYERS SQUIBB CO (BMY) is expected to grow by 478.44% in the next year.